An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
Christopher K. Zarins, MD; Dainis Krievins, MD, PhD
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
A new strategy based on identifying patients with silent coronary ischemia using coronary CT-derived FFR together with proactive ischemia-targeted coronary revascularization shows promise in reducing adverse cardiac events.
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Physician-led Collaboration Reinforces Ongoing Regulatory Activity and Clinical Advancement Across the Cardiovascular Portfolio
LATHAM, N.Y.--Feb. 3, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on...
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
Penumbra recently launched the Lightning Flash® 3.0 Computer Assisted Vacuum Thrombectomy (CAVT™) system, which includes significant upgrades that further advance our leading venous thromboembolism (VTE) platform.
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
MARLBOROUGH, Mass. and ALAMEDA, Calif. -- Boston Scientific Corporation and Penumbra, Inc., today announced the companies have entered into a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
First-of-its-Kind, Multi-Specialty Clinical Initiative Across IC, EP, Endovascular, Aortic, and Neurovascular
BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based medical device company redefining interventional...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
The GORE® VIABAHN® FORTEGRA Venous Stent is engineered to offer an optimal balance of conformability and compression resistance for treating a broad range of patients.
FLAGSTAFF, Ariz. (January 6, 2026) — W. L. Gore & Associates’...
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
MIDWAY 43 and MIDWAY 62 delivery catheters are designed to provide ideal tracking and a stable platform to support the delivery of various embolisation therapies in the neurovasculature.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
The research suggests that CAVT, a technology designed to rapidly remove blood clots via microprocessor-controlled aspiration, has the potential to help reduce healthcare costs.
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
Acquisition of SpectraWAVE’s next-generation technologies including HyperVueTM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary arteries, and X1TM-FFR, an AI-enabled...
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
The first pivotal trial implant of an investigational endovascular stent graft for the treatment of acute Type A dissections marks a critical milestone.
